Propranolol for the Treatment of Kaposi Sarcoma in Adults

Status Not yet recruiting

Clinical Trial Summary

Kaposi sarcoma (KS) lesions are initiated by endothelial cells infected with KS herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). Lesion progression is driven by abnormal angiogenesis, chronic inflammation, and uncontrolled cell proliferation. KS remains one of the most commonly diagnosed cancers in many African countries where economic constraints prevent successful treatment in most patients. Treatment outcomes in developed countries are also often unsatisfactory in HIV positive patients despite good virological and immunological responses to antiretroviral therapy. Therefore, identification of new oral, safe treatment options for treatment of KS remains a research priority. Given the known anti-angiogenic properties and based on the treatment response with other benign vascular lesions such as infantile hemangioma, propranolol is a good candidate for the treatment of KS. The hypothesis of this study is that treating patients with Kaposi sarcoma with propranolol will result in an overall response rate (complete response rate plus partial response rate) of at least 45%, and that propranolol will be safe and well tolerated in this patient population.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06445166
Study type	Interventional
Source	Washington University School of Medicine
Contact	Lee Ratner, M.D., Ph.D.
Phone	314-362-8836
Email	lratner@wustl.edu
Status	Not yet recruiting
Phase	Phase 2
Start date	September 30, 2024
Completion date	September 30, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04941274` - Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma	Phase 1/Phase 2
Completed	`NCT03160183` - Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
Recruiting	`NCT03993106` - A Study of sEphB4-HSA in Kaposi Sarcoma	Phase 2
Recruiting	`NCT05081141` - HHV8 and Solid Organ Transplantation
Completed	`NCT00395278` - Development of Serologic Assays for Human Herpes Virus-8
Recruiting	`NCT02408861` - Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Phase 1
Completed	`NCT03296553` - Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.	Phase 2
Recruiting	`NCT04305691` - Trial of Ixazomib for Kaposi Sarcoma	Phase 2
Completed	`NCT03316274` - Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma	Early Phase 1
Recruiting	`NCT05859074` - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer	Phase 1
Terminated	`NCT04893018` - NT-I7 for Kaposi Sarcoma in Patients With or Without HIV	Phase 1
Recruiting	`NCT06375122` - Natural History Study of Kaposi Sarcoma
Recruiting	`NCT05663502` - Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Recruiting	`NCT05329792` - L19IL2/L19TNF in Skin Cancer Patients	Phase 2
Not yet recruiting	`NCT05411237` - Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma	Phase 3
Completed	`NCT03050788` - Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma	N/A
Completed	`NCT03404297` - Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya	N/A
Terminated	`NCT01412515` - A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma	Phase 2
Not yet recruiting	`NCT06004011` - AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)	N/A
Withdrawn	`NCT02229981` - Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma	Phase 1/Phase 2